Cervical Cancer

Health care systems that adopted a higher volume of telehealth services less frequently used several low-value screening and diagnostic tests, according to results of a cohort study published in JAMA Internal Medicine.

Individuals with transportation insecurity appeared 41% less likely to undergo breast cancer screening than those without transportation difficulties, according to results of a cohort study.

From 2008 to 2022, the incidence of cervical precancers fell by 80% among screened women aged 20 to 24 years, supporting recommendations for HPV vaccination at ages 11 to 12 years, researchers wrote in Morbidity and Mortality Weekly Report.

Fewer than half of women who tested positive for HPV with negative cytological findings returned for a surveillance co-test within 1 year as recommended, yet more than half of those who received testing had HPV persistence or progression.

Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.

HPV-based screening was superior to cytology in preventing invasive cervical cancer in real-world settings in Sweden, according to a randomized trial published in Lancet Public Health.

The U.S. Preventive Services Task Force released a draft recommendation that women aged 21 to 65 years be regularly screened for cervical cancer.

A retrospective study of women who received mammograms between 2007 and 2016 at UC San Diego Health revealed that breast arterial calcification (BAC), which is visible on routine mammograms, could serve as a predictor for CVD risk.

Cervical cancer mortality among U.S. women younger than 25 years declined by 62% between 2013 and 2021, a finding largely attributed to the wide availability of HPV vaccination for this age cohort, researchers reported in JAMA.

The addition of cadonilimab to first-line chemotherapy improved outcomes among certain women with cervical cancer.